title: The neuroprotection of oxymatrine in cerebral ischemia/reperfusion is related to nuclear factor erythroid 2-related factor 2 (nrf2)-mediated antioxidant response: role of nrf2 and hemeoxygenase-1 expression.
abstract: Cerebral ischemia-reperfusion (CI/R) injury remains a major medical problem due to the lack of effective therapies. Previous studies have shown that increasing the activity of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and gene targets in cell culture and stroke animal models is highly neuroprotective. Oxymatrine is the major quinolizidine alkaloid extracted from the root of Sophora flavescens AIT, and has been proved to be protective after ischemia in recent studies. The present study was designed to investigate the potential effect of oxymatrine in ischemia-reperfusion injury in rat's brain and to explore the possible role of oxymatrine in Nrf2 pathway. The results indicated that the ischemic infarct and edema were significantly reduced in rats that received oxymatrine, with a corresponding improvement in neurological function after CI/R. In immunohistochemistry and Western blotting analyses, Nrf2 and hemeoxygenase-1 (HO-1) were up-regulated in ischemic cortex, beginning at 6 h, peaking at 48 h and declining at 72 h after CI/R. Intraperitoneal injection of oxymatrine inhibited the production of lipid peroxidation and increased the activities of Nrf2 and HO-1 in rats brain after CI/R. Taken together, these results suggest that oxymatrine administered systemically protected brain against focal ischemia-reperfusion damage at the early stage of stroke, and that activating Nrf2/HO-1 pathway may contribute to the neuroprotective action of oxymatrine in rat focal brain ischemia-reperfusion model. Thus, treatment of stroke with oxymatrine may prevent severe consequences after brain attack.
authors.affiliation: Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Xiangjian
authors.initials: X
authors.lastname: Zhang
authors.forename: Lili
authors.initials: L
authors.lastname: Cui
authors.forename: Rui
authors.initials: R
authors.lastname: Yang
authors.forename: Lina
authors.initials: L
authors.lastname: Wang
authors.forename: Lingling
authors.initials: L
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Du
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D000975:Antioxidants / Q000378:metabolism*; D015153:Blotting, Western; D002545:Brain Ischemia / Q000473:pathology / Q000517:prevention & control*; D051547:Heme Oxygenase-1 / Q000378:metabolism*; D007150:Immunohistochemistry; D051267:NF-E2-Related Factor 2 / Q000378:metabolism / Q000502:physiology*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D011807:Quinolizines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000473:pathology / Q000517:prevention & control*; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000975:Antioxidants; D051547:Heme Oxygenase-1; D051267:NF-E2-Related Factor 2; D018696:Neuroprotective Agents; D011807:Quinolizines; C495637:Nfe2l2 protein, rat; C037573:oxymatrine; D000093842:Matrines